美国前列腺消融技术协调注册网络构建共识
通过多轮德尔菲共识,15名泌尿肿瘤专家、FDA代表及HIFU厂商代表确定了前列腺消融技术协调注册网络的数据要素,涵盖人口学、治疗细节、肿瘤与功能结局及并发症,并选定IIEF-5、I-PSS、EPIC-26和MSHQ-EjD问卷,共识建议消融后约12个月行mpMRI和前列腺活检。
要点
- 共识确定注册网络需采集患者人口学、治疗细节、肿瘤结局、功能结局和并发症。
- 选用IIEF-5、I-PSS、EPIC-26和MSHQ-EjD问卷采集患者报告结局。
- 共识建议消融后约12个月行多参数MRI和前列腺活检,必要时额外检查。
核心结论
- 全国前列腺消融协调注册网络可为美国这一新兴治疗范式提供实践模式和结局数据。
- 多利益相关方共识确定了评估新旧能量模态和设备的关键要素。
研究设计与样本
- 多轮德尔菲共识方法,纳入15名专家泌尿科医生、FDA代表和高强度聚焦超声设备制造商领导层。
- 利益相关方在连续3轮中提供意见,每轮后召开电话会议就剩余条目达成共识。
主要发现
- 工作组就采集特定患者人口学、治疗细节、肿瘤结局、功能结局和并发症达成共识。
- 参与者同意最初为高强度聚焦超声开发的要素与其他前列腺消融技术兼容。
- 协调注册网络要素经审查并补充了FDA通用研究指标的数据要素。
关键数值与推荐
- 选用IIEF-5、I-PSS、EPIC-26和MSHQ-EjD问卷采集患者报告结局。
- 共识建议消融后约12个月获取随访多参数MRI和前列腺活检,并根据临床指征进行额外影像或活检。
临床怎么用
- 注册网络可用于收集前列腺消融技术的实践模式和结局数据。
- 共识要素可用于评估新的和现有的能量模态与设备。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The accumulation of data through a prospective, multicenter coordinated registry network is a practical way to gather real world evidence on the performance of novel prostate ablation technologies. Urological oncologists, targeted biopsy experts, industry representatives and representatives of the FDA (Food and Drug Administration) convened to discuss the role, feasibility and important data elements of a coordinated registry network to assess new and existing prostate ablation technologies. MATERIALS AND METHODS: A multiround Delphi consensus approach was performed which included the opinion of 15 expert urologists, representatives of the FDA and leadership from high intensity focused ultrasound device manufacturers. Stakeholders provided input in 3 consecutive rounds with conference calls following each round to obtain consensus on remaining items. Participants agreed that these elements initially developed for high intensity focused ultrasound are compatible with other prostate ablation technologies. Coordinated registry network elements were reviewed and supplemented with data elements from the FDA common study metrics. RESULTS: The working group reached consensus on capturing specific patient demographics, treatment details, oncologic outcomes, functional outcomes and complications. Validated health related quality of life questionnaires were selected to capture patient reported outcomes, including the IIEF-5 (International Index of Erectile Function-5), the I-PSS (International Prostate Symptom Score), the EPIC-26 (Expanded Prostate Cancer Index Composite-26) and the MSHQ-EjD (Male Sexual Health Questionnaire for Ejaculatory Dysfunction). Group consensus was to obtain followup multiparametric magnetic resonance imaging and prostate biopsy approximately 12 months after ablation with additional imaging or biopsy performed as clinically indicated. CONCLUSIONS: A national prostate ablation coordinated registry network brings forth vital practice pattern and outcomes data for this emerging treatment paradigm in the United States. Our multiple stakeholder consensus identifies critical elements to evaluate new and existing energy modalities and devices.
引用
- Golan R, Bernstein A, Sedrakyan A, et al. Development of a Nationally Representative Coordinated Registry Network for Prostate Ablation Technologies. J Urol. 2018. PMID: 29307684. doi:10.1016/j.juro.2017.12.058
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。